Attached files

file filename
EX-10.20 - EXHIBIT 10.20 - Mirati Therapeutics, Inc.mrtx-20151231xex1020.htm
EX-23.2 - EXHIBIT 23.2 - Mirati Therapeutics, Inc.mrtx-20151231xex232.htm
EX-31.2 - EXHIBIT 31.2 - Mirati Therapeutics, Inc.mrtx-20151231xex312.htm
EX-32.1 - EXHIBIT 32.1 - Mirati Therapeutics, Inc.mrtx-20151231xex321.htm
EX-31.1 - EXHIBIT 31.1 - Mirati Therapeutics, Inc.mrtx-20151231xex311.htm
10-K - 10-K - Mirati Therapeutics, Inc.mrtx-20151231x10k.htm


Exhibit 23.1


Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-3 No. 333-207848) of Mirati Therapeutics, Inc.,
(2)
Registration Statement (Form S-3 No. 333-206965) of Mirati Therapeutics, Inc.,
(3)
Registration Statement (Form S-3 No. 333-198678) of Mirati Therapeutics, Inc., 
(4)
Registration Statement (Form S-8 No. 333-204720) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics, Inc.,
(5)
Registration Statement (Form S-8 No. 333-189965) pertaining to the Amended and Restated Incentive Stock Option Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan of Mirati Therapeutics Inc., and
(6)
Registration Statement (Form S-8 No. 333-196487) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics Inc.;

of our report dated March 9, 2016, with respect to the consolidated financial statements of Mirati Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mirati Therapeutics, Inc. for the year ended December 31, 2015.

 
 
 
/s/ Ernst & Young LLP
 
San Diego, California
 
 
 
 
March 9, 2016